英科医疗(300677) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥1,572,919,050, a decrease of 31.25% compared to ¥2,287,865,174 in the same period last year[14] - The net profit attributable to shareholders was a loss of ¥153,056,715, representing a decline of 283.32% from a profit of ¥83,493,070 in the previous year[14] - Basic and diluted earnings per share were both -¥0.23, a decrease of 276.92% compared to ¥0.13 in the previous year[14] - The company reported a significant decline in net profit and cash flow, indicating challenges in operational performance[14] - Total revenue for Q1 2023 was approximately ¥1.57 billion, a decrease of 31.25% compared to ¥2.29 billion in Q1 2022[27] - The net profit for Q1 2023 was a loss of RMB 146,768,893.00, compared to a profit of RMB 79,471,291.00 in Q1 2022, reflecting a significant decline in profitability[51] Cash Flow and Operating Activities - The net cash flow from operating activities was a negative ¥174,585,120, down 141.90% from ¥416,703,728 in the same period last year[14] - Net cash flow from operating activities for Q1 2023 was -¥174.59 million, a decline of 141.90% compared to ¥416.70 million in Q1 2022, primarily due to a decrease in sales collections[27] - The company received cash related to operating activities amounting to ¥1,608,049,667, down from ¥2,183,935,286, a decrease of approximately 26.3%[40] - In the first quarter, the cash flow from operating activities was 1,383,659,242.00 CNY, a decrease from 1,977,957,759.00 CNY in the previous period[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥22,432,730,237, an increase of 4.44% from ¥21,478,748,819 at the end of the previous year[14] - The company’s total liabilities increased to RMB 6,527,111,500.00 from RMB 5,429,493,543.00, marking an increase of approximately 20.2%[49] - The equity attributable to shareholders decreased by 0.95% to ¥15,656,405,151 from ¥15,806,329,512 at the end of the previous year[14] - The company’s total equity as of March 31, 2023, was RMB 15,905,618,737.00, down from RMB 16,049,255,276.00 at the beginning of the year[49] Financing Activities - Cash flow from financing activities increased by 373.82% to ¥1.44 billion from ¥304.59 million, mainly due to an increase in bank loans during the reporting period[27] - Net cash flow from financing activities was ¥1,443,194,634, a substantial increase from ¥304,588,408, indicating strong financing support[40] Expenses and Costs - The total operating costs for Q1 2023 were RMB 1,744,533,179.00, down from RMB 2,186,961,202.00 in Q1 2022, indicating a reduction of approximately 20.2%[49] - The company experienced a 48.11% reduction in selling expenses, which fell to ¥50.85 million from ¥98.01 million, primarily due to decreased export costs[27] - Financial expenses rose by 129.55% to ¥43.59 million from ¥18.99 million, mainly due to increased exchange losses during the reporting period[27] - Research and development expenses for Q1 2023 were RMB 63,880,401.00, slightly down from RMB 69,568,207.00 in the previous year, showing a decrease of about 8.3%[51] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 72,471, with the largest shareholder holding 35.05%[28] - The company has repurchased a total of 14,002,107 shares, accounting for 2.1223% of the total share capital, with a total transaction amount of RMB 314,419,803.15[45] - The company plans to use between RMB 250 million and RMB 500 million for share repurchase to implement employee stock ownership plans and/or equity incentives[45] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - There is no indication of mergers or acquisitions in the current financial report[14] - The company plans to purchase liability insurance for its directors and senior management to enhance risk management and protect investor interests[44] - The impact of exchange rate changes on cash and cash equivalents was a loss of 78,944,203.00 CNY, compared to a loss of 26,412,769.00 CNY in the previous period[55] - The company’s first quarter report is unaudited[53]